NCT06068881View on ClinicalTrials.gov

"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an EZH2 Gain-of-function Genetic Mutation"

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

April 6, 2029

Study Completion Date

April 6, 2029

Conditions
Follicular LymphomaRefractory Follicular Lymphoma
Interventions
DRUG

Tazverik (Tazemetostat)

Oral Tablet

Sponsors

Lead Sponsor

Epizyme, Inc.

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Epizyme, Inc.

INDUSTRY

NCT06068881 - "A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an EZH2 Gain-of-function Genetic Mutation" | Biotech Hunter | Biotech Hunter